GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clovis Oncology Inc (FRA:C6O) » Definitions » Revenue per Share

Clovis Oncology (FRA:C6O) Revenue per Share : €0.90 (TTM As of Sep. 2022)


View and export this data going back to 2012. Start your Free Trial

What is Clovis Oncology Revenue per Share?

Clovis Oncology's revenue per share for the three months ended in Sep. 2022 was €0.21. Clovis Oncology's revenue per share for the trailing twelve months (TTM) ended in Sep. 2022 was €0.90.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for Clovis Oncology's Revenue per Share or its related term are showing as below:

FRA:C6O's 3-Year Revenue Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 3.65
* Ranked among companies with meaningful 3-Year Revenue Growth Rate only.

Clovis Oncology Revenue per Share Historical Data

The historical data trend for Clovis Oncology's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clovis Oncology Revenue per Share Chart

Clovis Oncology Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.00 1.61 2.39 1.60 1.14

Clovis Oncology Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.27 0.25 0.23 0.21 0.21

Competitive Comparison of Clovis Oncology's Revenue per Share

For the Biotechnology subindustry, Clovis Oncology's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clovis Oncology's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clovis Oncology's PS Ratio distribution charts can be found below:

* The bar in red indicates where Clovis Oncology's PS Ratio falls into.



Clovis Oncology Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Clovis Oncology's Revenue Per Share for the fiscal year that ended in Dec. 2021 is calculated as

Revenue Per Share (A: Dec. 2021 )=Revenue (A: Dec. 2021 )/Shares Outstanding (Diluted Average) (A: Dec. 2021 )
=131.65/115.528
=1.14

Clovis Oncology's Revenue Per Share for the quarter that ended in Sep. 2022 is calculated as

Revenue Per Share (Q: Sep. 2022 )=Revenue (Q: Sep. 2022 )/Shares Outstanding (Diluted Average) (Q: Sep. 2022 )
=30.97/144.625
=0.21

Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.90

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clovis Oncology  (FRA:C6O) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Clovis Oncology Revenue per Share Related Terms

Thank you for viewing the detailed overview of Clovis Oncology's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Clovis Oncology (FRA:C6O) Business Description

Traded in Other Exchanges
N/A
Address
5500 Flatiron Parkway, Suite 100, Boulder, CO, USA, 80301
Clovis Oncology Inc is a biopharmaceutical company. It is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, the EU, and additional international markets. The firm targets its development programs for the treatment of specific subsets of cancer populations. Its product candidate includes Rucaparib. Rucaparib is an oral small molecule inhibitor of poly ADP-ribose polymerase, is marketed in the United States for two indications specific to the recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. The company has two segments U.S and ex-U.S based on geograhic areas, with majority of its revenue coming from U.S.

Clovis Oncology (FRA:C6O) Headlines

No Headlines